1. Home
  2. SMBK vs LBRX Comparison

SMBK vs LBRX Comparison

Compare SMBK & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SmartFinancial Inc.

SMBK

SmartFinancial Inc.

HOLD

Current Price

$41.64

Market Cap

722.4M

Sector

Finance

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

SELL

Current Price

$28.07

Market Cap

850.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SMBK
LBRX
Founded
N/A
2015
Country
United States
United States
Employees
N/A
27
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
722.4M
850.5M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
SMBK
LBRX
Price
$41.64
$28.07
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$43.17
$46.60
AVG Volume (30 Days)
46.7K
127.7K
Earning Date
04-20-2026
05-06-2026
Dividend Yield
0.77%
N/A
EPS Growth
39.25
N/A
EPS
0.81
N/A
Revenue
N/A
N/A
Revenue This Year
$17.59
N/A
Revenue Next Year
$10.30
N/A
P/E Ratio
$51.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$30.75
$13.40
52 Week High
$43.91
$33.47

Technical Indicators

Market Signals
Indicator
SMBK
LBRX
Relative Strength Index (RSI) 53.10 43.90
Support Level $40.25 $22.39
Resistance Level $43.28 $33.47
Average True Range (ATR) 1.11 1.66
MACD -0.05 -0.67
Stochastic Oscillator 55.87 25.25

Price Performance

Historical Comparison
SMBK
LBRX

About SMBK SmartFinancial Inc.

SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: